Publication

Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer

de Boer, P. T., Frederix, G. W. J., Feenstra, T. L. & Vemer, P., Sep-2016, In : Pharmacoeconomics. 34, 9, p. 833-845 13 p.

Research output: Contribution to journalReview articleAcademicpeer-review

Background Transparent reporting of validation efforts of health economic models give stakeholders better insight into the credibility of model outcomes. In this study we reviewed recently published studies on seasonal influenza and early breast cancer in order to gain insight into the reporting of model validation efforts in the overall health economic literature.

Methods A literature search was performed in Pubmed and Embase to retrieve health economic modelling studies published between 2008 and 2014. Reporting on model validation was evaluated by checking for the word validation, and by using AdViSHE (Assessment of the Validation Status of Health Economic decision models), a tool containing a structured list of relevant items for validation. Additionally, we contacted corresponding authors to ask whether more validation efforts were performed other than those reported in the manuscripts.

Results A total of 53 studies on seasonal influenza and 41 studies on early breast cancer were included in our review. The word validation was used in 16 studies (30 %) on seasonal influenza and 23 studies (56 %) on early breast cancer; however, in a minority of studies, this referred to a model validation technique. Fifty-seven percent of seasonal influenza studies and 71 % of early breast cancer studies reported one or more validation techniques. Cross-validation of study outcomes was found most often. A limited number of studies reported on model validation efforts, although good examples were identified. Author comments indicated that more validation techniques were performed than those reported in the manuscripts.

Conclusions Although validation is deemed important by many researchers, this is not reflected in the reporting habits of health economic modelling studies. Systematic reporting of validation efforts would be desirable to further enhance decision makers' confidence in health economic models and their outcomes.

Original languageEnglish
Pages (from-to)833-845
Number of pages13
JournalPharmacoeconomics
Volume34
Issue number9
Publication statusPublished - Sep-2016

    Keywords

  • COST-EFFECTIVENESS ANALYSIS, ADJUVANT TRASTUZUMAB THERAPY, DYNAMIC TRANSMISSION MODEL, AGED 50-64 YEARS, POSTMENOPAUSAL WOMEN, VACCINATION PROGRAM, PREGNANT-WOMEN, TECHNOLOGY-ASSESSMENT, ENDOCRINE THERAPY, UTILITY ANALYSIS

Download statistics

No data available

ID: 32034277